Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oxazolidinone antibiotic containing parallel rings

An alkyl and alkylamine-based technology, applied in the field of medicine, can solve the problems of linezolid drug resistance, single oxazolidinone antibiotics, and inability to meet clinical medication requirements

Inactive Publication Date: 2011-08-17
SHANDONG XUANZHU PHARMA TECH CO LTD
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, clinically, the drug resistance of Gram-positive bacteria is becoming more and more serious, and the clinical drug variety of oxazolidinone antibiotics is very single, which cannot meet the clinical requirements, and the drug resistance of linezolid is also emerging

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oxazolidinone antibiotic containing parallel rings
  • Oxazolidinone antibiotic containing parallel rings
  • Oxazolidinone antibiotic containing parallel rings

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0161] Example 1 (S)-N-[[3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene Base]-2-oxo-5-oxazole Preparation of alkyl] methyl] acetamide

[0162]

[0163] Add 30 mL of 1,4-dioxane to the dry reaction flask, (S)N-[[3-(3-fluoro-4-bromophenyl)-2-oxo-5-oxazolidinyl ] methyl] acetamide 3.31g (10mmol), bis-valeryl diborane 2.54g (10mmol), potassium acetate 0.98g (10mmol), feed argon into the reaction flask, then add Pd (PPh 3 ) 2 Cl 2 0.3g, continue to feed argon into the reaction solution, stir the reaction overnight at 90°C, cool to room temperature, filter with diatomaceous earth, extract with ethyl acetate and brine, dry and concentrate the organic layer with anhydrous sodium sulfate, and precipitate a gray solid , 3.22 g of the product was obtained with a yield of 85.2%. ((S)-N-[[3-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2 used in the following examples -base) phenyl]-2-oxo-5-oxazolidinyl] methyl] the preparation of acetamide is prepare...

Embodiment 2

[0164] Example 2N-[[(5S)-3-[4-[1-[(1H-1,2,3-triazol-5-yl)methanamine]-2,3-two Hydrogen-1H-inden-5-yl]-3-fluorophenyl]-2- Preparation of oxo-5-oxazolidinyl]methyl]acetamide hydrochloride (compound 1 hydrochloride)

[0165]

[0166] (1) Preparation of 5-bromo-N-(2-propynyl)-2,3-dihydro-1H-inden-1-amine

[0167]

[0168] Dissolve propargylamine (6.6g, 0.12mol) and 5-bromo-1-indanone (22.9g, 0.109mmol) in 1,2-dichloroethane (300mL), and add to it under an ice-water bath Add NaBH(OAc) 3 (43.3g, 203mmol), after the addition, the mixture was stirred and reacted at room temperature for 40 hours, the organic phase was washed with water (50mL×2) and NaCl (150mL×2) successively, dried over anhydrous magnesium sulfate, and the organic phase was used directly without purification in the next step.

[0169] (2) Preparation of tert-butyl 5-bromo-2,3-dihydro-1H-inden-1-yl (2-propynyl) carbamate

[0170]

[0171] 5-Bromo-N-(2-propynyl)-2,3-dihydro-1H-inden-1-amine (8.9 g, 0.0...

Embodiment 3

[0186] Example 3N-[[(5S)-3-[4-[1-[2-(1H-1,2,3-triazol-5-yl)ethyl]indoline-5-yl]-3 -Fluorophenyl]-2-oxo - Preparation of 5-oxazolidinyl] methyl] acetamide (compound 2)

[0187]

[0188] (1) Preparation of 3-butynyl methanesulfonate

[0189]

[0190] In a 250mL reaction flask, dissolve 0.500g (7.13mmol) of 3-butyn-1-ol and 2.17g (21.4mmol) of triethylamine with 90mL of dichloromethane, and slowly add methanesulfonyl chloride 1.06 g (9.23mmol), added dropwise for about 30 minutes, stirred at room temperature overnight (16 hours) after removing the cooling bath, the organic phase was washed with 1M HCl (aqueous solution) and sodium chloride successively, then dried with anhydrous magnesium sulfate, and filtered After the solvent was removed under reduced pressure, 1.02 g of oily 3-butynyl methanesulfonate was obtained, with a yield of 96%.

[0191] (2) Preparation of 5-bromo-1-(3-butynyl)indoline

[0192]

[0193] Add Na to a toluene solution (40mL) of 4.95g (25mmo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to technical field of medicaments, in particular to relates to an oxazolidinone antibiotic containing parallel rings as shown in a general formula (I) and a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R1,R2, R3, R4, R5, R6, an A ring, a B ring and -Y- are defined in the specification. The invention also relates to a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds in preparing medicaments for treating and / or preventing infectious diseases.

Description

1. Technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to oxazolidinone antibiotics containing parallel rings, pharmaceutically acceptable salts or stereoisomers thereof, preparation methods of these compounds, pharmaceutical compositions containing these compounds, and these compounds Use in the preparation of medicines for treating and / or preventing infectious diseases. 2. Background technology [0002] Oxazolidinone antibacterial drugs are a new type of chemically synthesized antibacterial drugs developed after sulfonamides and fluoroquinolones, which can inhibit multi-drug resistant Gram-positive bacteria. [0003] Linezolid is the first marketed oxazolidinone antibiotic, which has a strong inhibitory effect on Gram-positive bacteria and has no cross-resistance with other antibacterial drugs. The unique mechanism of action inhibits the early stages of bacterial protein synthesis. It is mainly used for the treatment...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D413/12C07D413/14C07D413/10C07D417/14C07D471/04C07D513/04A61K31/422A61K31/4709A61K31/4725A61K31/428A61K31/423A61K31/498A61K31/517A61K31/435A61K31/437A61P31/04
CPCC07D471/04C07D413/12C07D413/14C07D513/04C07D417/14A61P31/04
Inventor 黄振华
Owner SHANDONG XUANZHU PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com